SuperworthAdaptive Biotechnologies market cap ADPT
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $4.1B
- Highest close in our data
- $9.3B
- Jan 2021
Adaptive Biotechnologies is worth $4.1B at the close on Oct 23, 2026, at $25.51 a share.
That is up 55% over the last year and down 13% over five years.
Its highest close in our data was $9.3B in Jan 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $4.1B | $1.9B | $4.7B | +60% |
| 2025 | $2.5B | $959.3M | $3B | +175% |
| 2024 | $928.3M | $348.2M | $943M | +31% |
| 2023 | $709.4M | $508.2M | $1.4B | −35% |
| 2022 | $1.1B | $894.4M | $3.3B | −72% |
| 2021 | $4B | $3.6B | $9.3B | −51% |
| 2020 | $8.1B | $2.5B | $8.6B | +122% |
| 2019 | $3.6B | $3.2B | $6.3B | n/a |
Against its peers
Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first, today.
| Company | Market cap |
|---|---|
| ADPTAdaptive Biotechnologies | $4.1B |
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| MGTXMeiraGTx | $884.6M |
| INCYIncyte | $23.5B |
| Peer median | $10.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Adaptive Biotechnologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.